Sign in

    Elizabeth Scott

    Research Analyst at SVB Securities

    Elizabeth Scott is an Analyst at SVB Securities, specializing in equity research within the healthcare and biotechnology sectors. Her coverage includes emerging biotech companies, where she delivers insights on pipeline developments and clinical milestones, though public records do not reflect third-party tracked performance metrics or formal analyst rankings. After beginning her career in life sciences research, she joined SVB Securities to focus on data-driven healthcare investment analysis and has developed credibility through detailed sector coverage. Elizabeth holds relevant FINRA securities licenses and leverages her scientific background to bridge technical research with investor decision-making, but additional public recognition or industry awards have not been widely reported.

    Elizabeth Scott's questions to SELB leadership

    Elizabeth Scott's questions to SELB leadership • Q3 2022

    Question

    Elizabeth Scott of SVB Securities inquired about the expectations for the upcoming SEL-212 Phase III readout, specifically the anticipated serum uric acid response rate, anti-drug antibody mitigation, and any available data on discontinuation rates.

    Answer

    President and CEO Carsten Brunn expressed confidence, citing prior Phase II trials that showed response rates in the mid-60% range. He clarified that the primary endpoint is serum uric acid (SUA) levels at Month 6, not anti-drug antibodies (ADAs). Brunn noted the company is blinded to the Phase III discontinuation rates and will report top-line data in Q1 2023.

    Ask Fintool Equity Research AI